Support your Life Science business from scouting for assets to deal closure

At a glance

  • Specialized and customized consulting services within Life Sciences and Healthcare
  • Provide full turnkey business development solution to Chinese and Western healthcare companies from scouting to deal closure
  • Help facilitate deal making between Chinese and Western firms including in & outlicensing, investment, strategic partnering and M&A
  • Provide integrated strategic consultancy and implementation plans
LEARN MORE

What we do

GoQing combines the right business development and pharma/healthcare scientific capabilities to help you with:

Scouting and finding cutting-edge assets

Assessing the investment assets (due diligence)

Executing the deal to the right products / platform technology / company

30+

years experience within Pharma and Healthcare supported by consultants and experts in EU, US and CN

Contact Us

Our Services

Growing inorganically can help your company pivot, innovate and growth fast. However, it is a complex process that requires knowledge of market, players, assets development and where a deal must be done fast and at the right time. We can help you be ahead with customized solutions, achieve your business objectives and create long term value through M&A, licensing, investment, and strategic partnering.

We advise clients in CN, US and EU

Chinese Pharma companies looking to expand / strengthen their portfolio in CN with novel “best-in-class” or “first-in-class” candidates/platforms with clinical POC established in US or EU
Chinese Biotechs with proprietary innovative or “first-in-class” platform / clinical assets and who are looking for a partner in the US or EU for development and commercialization outside CN
Western Biotechs with proprietary cutting edge platforms / development candidates and with interest to partner for development and/or commercialization in CN or globally
Western Life Sciences companies looking to invest or acquire small start-ups / biotechs with proprietary cutting edge platforms, development assets and/or commercial products with promising growth potential